Compare MLYS & DXYZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLYS | DXYZ |
|---|---|---|
| Founded | 2019 | N/A |
| Country | United States | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 447.0M |
| IPO Year | 2023 | 2024 |
| Metric | MLYS | DXYZ |
|---|---|---|
| Price | $33.13 | $27.19 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $47.33 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | N/A |
| Earning Date | 02-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.24 | N/A |
| 52 Week High | $47.65 | N/A |
| Indicator | MLYS | DXYZ |
|---|---|---|
| Relative Strength Index (RSI) | 29.64 | 42.08 |
| Support Level | $34.21 | $30.10 |
| Resistance Level | $37.70 | $32.98 |
| Average True Range (ATR) | 1.56 | 1.87 |
| MACD | -0.13 | -0.74 |
| Stochastic Oscillator | 14.42 | 3.39 |
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It invests in a portfolio of what is believed to be 100 of the top venture-backed private technology companies.